Berkshire Hathaway's Q2 Net Earnings Fall, Revenue Rises-March 2024-www.financetom.com

Berkshire Hathaway's Q2 Net Earnings Fall, Revenue Rises

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Berkshire Hathaway's Q2 Net Earnings Fall, Revenue Rises

Aug 5, 2024 3:35 AM

06:05 AM EDT, 08/05/2024 (MT Newswires) -- Berkshire Hathaway (BRK.A) reported Q2 net earnings Saturday of $21,122 per average equivalent class A share, down from $24,774 a year earlier.

Two analysts polled by Capital IQ expected $15,168.

Revenue for the quarter ended June 30 was $93.65 billion, compared with $92.50 billion a year earlier.

Two analysts surveyed by Capital IQ expected $88.49 billion.

Previous page： Market Chatter: Nvidia Invested $1 Billion in AI Companies in 2024 Next page：

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Market Chatter: Nvidia Invested $1 Billion in AI Companies in 2024

Jan 2, 2025

07:07 AM EST, 01/02/2025 (MT Newswires) -- Nvidia ( NVDA ) invested an aggregate of $1 billion in artificial intelligence companies last year that ranged across 50 start-up funding rounds and numerous corporate agreements, the Financial Times reported Wednesday, citing filings and Dealroom research. In 2023, Nvidia ( NVDA ) spent a total of $872 million across 39 start-up rounds,...

Jan 2, 2025

...

Cameco, Kazatomprom JV Inkai Suspends Uranium Production Due to Regulatory Delays

Jan 2, 2025

07:08 AM EST, 01/02/2025 (MT Newswires) -- Cameco ( CCJ ) said Thursday that its joint venture with Kazatomprom, Joint Venture Inkai suspended uranium production operations as of Wednesday. The decision was made after JV Inkai failed to receive an extension to submit updated Project for Uranium Deposit Development documentation to Kazakhstan's Ministry of Energy by the year-end deadline. Cameco...

Neumora Therapeutics' depression drug fails to meet main goal of late-stage study

Jan 2, 2025

Jan 2 (Reuters) - Neumora Therapeutics ( NMRA ) said on Thursday its experimental drug to treat depression failed to meet the main goal of a late-stage study. ...